Patient Disease Characteristics and Treatment Patterns in Mild–Moderate Psoriasis: Results from Real-World Clinical Practice in the United States (PROSPECT Study)
Open Access
- 17 February 2025
- journal article
- research article
- Published by Springer Nature in Dermatology and Therapy
- Vol. 15 (3) , 663-680
Abstract
Introduction Psoriasis (PsO) is a common dermatological condition. Psoriasis severity is commonly characterized by percentage body surface area (BSA) affected, with < 3% BSA considered mild disease and 3–10% moderate disease. Treatment options for and knowledge of clinical practice patterns in patients with mild PsO are limited. Here, we use real-world data to characterize patients diagnosed with mild and moderate PsO and their clinical management. Methods Data were derived from the Adelphi Real World PsO Disease Specific Programme™, a cross-sectional survey of dermatologists and adult patients with PsO in the USA, between December 2021 and March 2022. Dermatologists reported demographic and clinical details. Patients reported treatment satisfaction and quality of life using patient-reported outcome measures. Patients were stratified by physician-reported severity at diagnosis (mild/moderate) and compared using bivariate analyses. Results Out of 389 patients, 18.5% were diagnosed with mild PsO. The majority were female, white, and employed. Patients diagnosed with moderate PsO had higher body mass index (p = 0.002) and longer disease duration (p = 0.041). Only 22.0% of patients diagnosed with mild PsO had BSA < 3% at diagnosis, and 48.1% of patients diagnosed as moderate PsO had BSA < 10%. BSA improvement following initiation of current treatment was higher among patients diagnosed with moderate PsO (p < 0.001). Those diagnosed with moderate PsO more commonly had involvement of the elbows (p = 0.003), legs (p = 0.002), knees (p < 0.001), soles (p = 0.035), and back (p = 0.004) at diagnosis. Cracked skin, redness, and tender skin (p < 0.001 for all) were more common among those diagnosed with moderate PsO. Both groups mostly received topical agents; however, those diagnosed with moderate PsO more commonly received systemic (p < 0.001) or biologic (p = 0.002) treatment. Patients diagnosed with moderate PsO had lower EQ-5D-5L (p = 0.014) and treatment satisfaction (p = 0.007) scores. Conclusion These findings suggest that physicians routinely underestimate PsO severity, resulting in possible undertreatment, suboptimal outcomes, and quality-of-life impairments for patients with milder severity PsO.Keywords
Funding Information
- Johnson & Johnson Innovative Medicine United States
This publication has 32 references indexed in Scilit:
- Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measuresJournal of the American Academy of Dermatology, 2021
- US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samplesQuality of Life Research, 2020
- Pathophysiology, Clinical Presentation, and Treatment of PsoriasisJAMA, 2020
- Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis CouncilJournal of the American Academy of Dermatology, 2020
- United States Valuation of EQ-5D-5L Health States Using an International ProtocolValue in Health, 2019
- Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologicsJournal of the American Academy of Dermatology, 2019
- Real-world burden of comorbidities in US patients with psoriasisJournal of the American Academy of Dermatology, 2017
- Under-Treatment of Patients with Moderate to Severe Psoriasis in the United States: Analysis of Medication Usage with Health Plan DataDermatology and Therapy, 2016
- Undertreatment, Treatment Trends, and Treatment Dissatisfaction Among Patients With Psoriasis and Psoriatic Arthritis in the United StatesJAMA Dermatology, 2013
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990